Stockreport

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

Oric Pharmaceuticals, Inc.  (ORIC) 
PDF Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC- [Read more]